The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance

INIS

• cancer 100%
• prostate 85%
• inhibition 42%
• in vivo 28%
• in vitro 28%
• tumors 28%
• polymerization 28%
• sulfonamides 28%
• toluidines 28%
• drugs 14%
• stability 14%
• patients 14%
• dynamics 14%
• induction 14%
• accumulation 14%
• lungs 14%
• viability 14%
• apoptosis 14%
• cell cycle 14%
• proliferation 14%
• microtubules 14%
• doxorubicin 14%
• cleavage 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Prostate Cancer 85%
• Docetaxel 42%
• Tubulin 42%
• Enalapril Maleate 28%
• Toluidine Derivative 28%
• Sulfonamide 28%
• Multidrug Resistance Protein 1 28%
• Paclitaxel 14%
• Tumor Growth 14%
• Doxorubicin 14%
• Drug Resistance 14%
• Cancer Inhibition 14%
• Vincristine 14%
• Taxane 14%
• Lung Cancer 14%
• Apoptosis 14%
• Cell Cycle 14%

Biochemistry, Genetics and Molecular Biology

• Electric Potential 28%
• Drug Resistance 28%
• Microtubule Assembly 28%
• Sulfonamide 28%
• Apoptosis 14%
• Cancer Cell 14%
• Immunofluorescence 14%
• Poly ADP Ribose Polymerase 14%
• Doxorubicin 14%
• Cell Viability 14%
• Cell-Cycle Analysis 14%
• Dynamics 14%
• Tubulin 14%